Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral liarozole versus placebo for lamellar ichthyosis
2005-000842-35Phase 2Completed
- Sponsor
- Barrier Therapeutics, Inc.
- Start
- Aug 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Liarozole in lamellar ichthyosis (LI) (3 arms), sponsored by Barrier Therapeutics, Inc. Primary endpoints: Primary efficacy endpoint and Investigator's Global Assessment at 12 weeks. Started Aug 2005; status: completed.
02
Drugs
Liarozole
03
Conditions
lamellar ichthyosis (LI)
Beyond the preview
Go deeper on 2005-000842-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000842-35.